Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- CEO of Teva-Takeda JV Confident on Handling Both Long-Listed Brands, Generics
August 17, 2016
- Ethical Drug Sales Down 0.8% in June: Crecon Report
August 17, 2016
- Mitsubishi Tanabe to Focus on Sales Turnaround for Canaglu, Eyes Diabetes and Nephrology Sales of 100 Bil. Yen
August 17, 2016
- Taiho Phama Subsidiary Gets Approval for Uzel AG
August 16, 2016
- Japan NDA Filed for Gilead’s HIV Drug Descovy
August 16, 2016
- Oncolys, NCC Hospital East to Run Investigator-Led Trial on Oncolytic Virus
August 15, 2016
- AnGes MG, Vical to Form Biz Tie-Up over DNA Vaccines
August 15, 2016
- Shionogi Begins Distribution of Ethical Isodine Products: Mundipharma
August 15, 2016
- Teijin Gets Japan Rights to Versartis’ Growth Hormone Deficiency Treatment
August 15, 2016
- JT/Torii License Menlo’s Pruritus Candidate for Japan Market
August 15, 2016
- Sawai Eyes First-to-File Status for 5 Generics in the US
August 10, 2016
- Japan PII Now Underway for Otsuka’s DMD Candidate TAS-205
August 10, 2016
- Otsuka Suffers Big Drops in Pharma Sales, Profit on US Abilify Patent Loss
August 10, 2016
- Astellas Files Japan NDA for Quetiapine for Bipolar Disorder
August 10, 2016
- Kissei, JCR Kick Off Japan PIII for Nesp Biosimilar
August 10, 2016
- Eisai, Biogen to Launch Global PIII for Alzheimer’s Drug by March-End
August 10, 2016
- Ono Rushes to Soothe Investor Nerves over Opdivo PIII Data
August 10, 2016
- Opdivo Disappoints in 1st-Line Lung Cancer Trial
August 9, 2016
- Carna Biosciences, Janssen Call Off Licensing Deal for Kinase Inhibitor
August 8, 2016
- Takeda, Pfizer to Wind Up Sales Deal for Prevenar, BeneFIX
August 8, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…